About Spring Bank Pharmaceuticals (NASDAQ:SBPH)
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases. The Company's SB 9200 selectively activates within infected cells the cellular proteins retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company is also developing a second SMNH product candidate, SB 11285, as an immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes (STING) pathway. The Company focuses on developing SB 9200 for the treatment of chronic hepatitis B virus (HBV).
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SBPH
CUSIPN/A
Phone508-473-5993
Debt
Debt-to-Equity RatioN/A
Current Ratio11.54%
Quick Ratio11.54%
Price-To-Earnings
Trailing P/E Ratio-7.63
Forward P/E Ratio-5.95
P/E GrowthN/A
Sales & Book Value
Annual Sales$350,000.00
Price / Sales528.40
Cash FlowN/A
Price / CashN/A
Book Value$2.68 per share
Price / Book5.32
Profitability
EPS (Most Recent Fiscal Year)($1.87)
Net Income$-27,670,000.00
Net MarginsN/A
Return on Equity-69.68%
Return on Assets-44.86%
Miscellaneous
Employees21
Outstanding Shares12,960,000
Spring Bank Pharmaceuticals (NASDAQ:SBPH) Frequently Asked Questions
What is Spring Bank Pharmaceuticals' stock symbol?
Spring Bank Pharmaceuticals trades on the NASDAQ under the ticker symbol "SBPH."
How were Spring Bank Pharmaceuticals' earnings last quarter?
Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) posted its quarterly earnings results on Tuesday, February, 20th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.65) by $0.18. View Spring Bank Pharmaceuticals' Earnings History.
What price target have analysts set for SBPH?
5 Wall Street analysts have issued 1 year price objectives for Spring Bank Pharmaceuticals' shares. Their forecasts range from $20.00 to $32.00. On average, they expect Spring Bank Pharmaceuticals' stock price to reach $28.00 in the next year. View Analyst Ratings for Spring Bank Pharmaceuticals.
Who are some of Spring Bank Pharmaceuticals' key competitors?
Some companies that are related to Spring Bank Pharmaceuticals include GTX (GTXI), Clearside Biomedical (CLSD), Dermira (DERM), Paratek Pharmaceuticals (PRTK), Strongbridge Biopharma (SBBP), Catalyst Biosciences (CBIO), Merus (MRUS), Kadmon (KDMN), Durect (DRRX), Seres Therapeutics (MCRB), BioSpecifics Technologies (BSTC), AVEO Pharmaceuticals (AVEO), Celyad (CYAD), Zymeworks (ZYME), Arbutus Biopharma (ABUS), Aquinox Pharmaceuticals (AQXP), Avadel Pharmaceuticals (AVDL) and Savara (SVRA).
When did Spring Bank Pharmaceuticals IPO?
(SBPH) raised $14 million in an initial public offering on Friday, May 6th 2016. The company issued 1,100,000 shares at a price of $12.00-$14.00 per share. Dawson James Securities acted as the underwriter for the IPO.
Has Spring Bank Pharmaceuticals been receiving favorable news coverage?
News coverage about SBPH stock has trended somewhat positive this week, according to Accern. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Spring Bank Pharmaceuticals earned a media sentiment score of 0.02 on Accern's scale. They also gave news headlines about the company an impact score of 46.28 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
How do I buy shares of Spring Bank Pharmaceuticals?
Shares of SBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spring Bank Pharmaceuticals' stock price today?
One share of SBPH stock can currently be purchased for approximately $14.27.
How big of a company is Spring Bank Pharmaceuticals?
Spring Bank Pharmaceuticals has a market capitalization of $184.86 million and generates $350,000.00 in revenue each year. The company earns $-27,670,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. Spring Bank Pharmaceuticals employs 21 workers across the globe.
How can I contact Spring Bank Pharmaceuticals?
Spring Bank Pharmaceuticals' mailing address is 86 South Street, Hopkinton MA, 01748. The company can be reached via phone at 508-473-5993.
MarketBeat Community Rating for Spring Bank Pharmaceuticals (SBPH)
MarketBeat's community ratings are surveys of what our community members think about Spring Bank Pharmaceuticals and other stocks. Vote "Outperform" if you believe SBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Spring Bank Pharmaceuticals in the last 12 months. Their average twelve-month price target is $28.00, suggesting that the stock has a possible upside of 96.22%. The high price target for SBPH is $32.00 and the low price target for SBPH is $20.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.80 | 2.80 | 2.80 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $28.00 | $28.00 | $27.25 | $26.3333 |
| Price Target Upside: | 96.22% upside | 138.30% upside | 60.11% upside | 73.02% upside |
Spring Bank Pharmaceuticals (NASDAQ:SBPH) Consensus Price Target History
Spring Bank Pharmaceuticals (NASDAQ:SBPH) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Spring Bank Pharmaceuticals (NASDAQ:SBPH) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Spring Bank Pharmaceuticals (NASDAQ SBPH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 17.60%
Institutional Ownership Percentage: 28.65%
Spring Bank Pharmaceuticals (NASDAQ SBPH) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/28/2018 | Martin J Driscoll | Insider | Buy | 1,000 | $12.83 | $12,830.00 | |  |
| 9/14/2017 | Martin J Driscoll | Insider | Buy | 1,000 | $14.84 | $14,840.00 | 55,400 | |
| 8/4/2017 | David Arkowitz | Director | Buy | 2,500 | $12.24 | $30,600.00 | 17,086 | |
| 8/3/2017 | Martin J Driscoll | Insider | Buy | 2,000 | $12.36 | $24,720.00 | 53,400 | |
| 6/27/2017 | Kurt M Eichler | Director | Buy | 76,923 | $13.00 | $999,999.00 | 582,533 | |
| 3/7/2017 | Martin J Driscoll | Insider | Buy | 2,000 | $9.44 | $18,880.00 | 52,400 | |
| 2/23/2017 | Kurt M Eichler | Director | Buy | 1,200 | $8.76 | $10,512.00 | 505,610 | |
| 12/15/2016 | Martin J Driscoll | Insider | Buy | 2,000 | $8.50 | $17,000.00 | 50,400 | |
| 11/30/2016 | Martin J Driscoll | Insider | Buy | 2,000 | $7.98 | $15,960.00 | 48,400 | |
| 11/9/2016 | Kurt M Eichler | Director | Buy | 7,000 | $8.69 | $60,830.00 | 437,990 | |
| 11/9/2016 | Martin J Driscoll | Insider | Buy | 2,000 | $8.84 | $17,680.00 | 24,500 | |
| 9/19/2016 | Kurt M Eichler | Director | Buy | 1,996 | $12.50 | $24,950.00 | 429,644 | |
| 9/14/2016 | Kurt M Eichler | Director | Buy | 514 | $12.50 | $6,425.00 | 428,994 | |
| 9/13/2016 | Kurt M Eichler | Director | Buy | 490 | $12.50 | $6,125.00 | 428,480 | |
| 9/9/2016 | Nezam H Afdhal | Insider | Buy | 2,400 | $12.50 | $30,000.00 | 40,150 | |
| 9/2/2016 | Martin J Driscoll | Insider | Buy | 1,000 | $11.75 | $11,750.00 | 22,500 | |
| 8/30/2016 | Martin J Driscoll | Insider | Buy | 1,000 | $12.41 | $12,410.00 | 21,500 | |
| 8/24/2016 | Nezam H Afdhal | Insider | Buy | 2,000 | $11.92 | $23,840.00 | 37,300 | |
| 8/23/2016 | Jonathan Freve | CFO | Buy | 1,000 | $10.74 | $10,740.00 | 2,000 | |
| 8/23/2016 | Kurt M Eichler | Director | Buy | 3,000 | $10.73 | $32,190.00 | 427,990 | |
| 8/22/2016 | Martin J Driscoll | Insider | Buy | 2,000 | $11.43 | $22,860.00 | 19,500 | |
| 8/16/2016 | Nezam H Afdhal | Insider | Buy | 1,900 | $11.43 | $21,717.00 | 35,650 | |
| 8/12/2016 | Nezam H Afdhal | Insider | Buy | 2,600 | $11.33 | $29,458.00 | 33,850 | |
| 8/9/2016 | Martin J Driscoll | Insider | Buy | 2,000 | $11.03 | $22,060.00 | 15,500 | |
| 8/4/2016 | Jonathan Freve | CFO | Buy | 1,000 | $9.75 | $9,750.00 | 1,000 | |
| 8/4/2016 | Martin J Driscoll | Insider | Buy | 2,000 | $9.96 | $19,920.00 | 13,500 | |
| 5/11/2016 | Kurt M Eichler | Director | Buy | 41,666 | $12.00 | $499,992.00 | 423,990 | |
| 5/11/2016 | Martin J Driscoll | CEO | Buy | 12,500 | $12.00 | $150,000.00 | 12,500 | |
(Data available from 1/1/2013 forward)
Spring Bank Pharmaceuticals (NASDAQ SBPH) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Zacks: Analysts Expect Spring Bank Pharmaceuticals Inc (SBPH) to Post -$0.52 EPS
www.americanbankingnews.com - April 20 at 3:14 PM |
 | Spring Bank Announces Expanded Inarigivir Data from the ACHIEVE Trial to Be Presented at The International Liver Congress™
finance.yahoo.com - April 18 at 10:03 AM |
| Spring Bank Pharmaceuticals (SBPH) PT Lowered to $30.00 at Chardan Capital
www.americanbankingnews.com - April 14 at 3:38 PM |
| Contrasting Spring Bank Pharmaceuticals (SBPH) & Rhythm Pharmaceuticals (RYTM)
www.americanbankingnews.com - April 13 at 3:15 AM |
| Spring Bank Pharmaceuticals (SBPH) Downgraded by ValuEngine
www.americanbankingnews.com - April 10 at 7:17 PM |
| Spring Bank Pharmaceuticals (SBPH) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - April 5 at 10:26 AM |
| Spring Bank Pharmaceuticals Inc (SBPH) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 5 at 10:15 AM |
| Analysts Anticipate Spring Bank Pharmaceuticals Inc (SBPH) to Post -$0.52 EPS
www.americanbankingnews.com - April 3 at 3:10 PM |
| Spring Bank Pharmaceuticals (SBPH) Now Covered by B. Riley
www.americanbankingnews.com - April 1 at 8:42 PM |
| Spring Bank Pharmaceuticals' (SBPH) Buy Rating Reaffirmed at Chardan Capital
www.americanbankingnews.com - April 1 at 7:35 PM |
| Edited Transcript of SBPH earnings conference call or presentation 21-Feb-18 1:30pm GMT
finance.yahoo.com - April 1 at 9:51 AM |
| Zacks: Analysts Anticipate Spring Bank Pharmaceuticals Inc (SBPH) Will Post Earnings of -$0.52 Per Share
www.americanbankingnews.com - March 17 at 1:30 PM |
| Spring Bank Announces Presentation of Combined Inarigivir 25 mg and 50 mg 12 and 24 Week ACHIEVE Results Demonstrating Enhanced Anti-Viral Efficacy in HBeAg-Negative Patients
finance.yahoo.com - March 14 at 12:39 PM |
| Spring Bank Pharmaceuticals Inc (SBPH) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - March 11 at 10:10 AM |
| Head-To-Head Comparison: Auspex Pharmaceuticals (ASPX) & Spring Bank Pharmaceuticals (SBPH)
www.americanbankingnews.com - March 10 at 9:22 PM |
| Spring Bank Pharmaceuticals Appoints Timothy Clackson, Ph.D., to its Board of Directors
finance.yahoo.com - March 5 at 4:24 PM |
| Spring Bank Pharmaceuticals Inc (SBPH) Insider Martin J. Driscoll Acquires 1,000 Shares
www.americanbankingnews.com - March 1 at 10:44 PM |
| Zacks: Brokerages Anticipate Spring Bank Pharmaceuticals Inc (SBPH) to Post -$0.52 Earnings Per Share
www.americanbankingnews.com - February 28 at 1:40 PM |
| William Blair Brokers Boost Earnings Estimates for Spring Bank Pharmaceuticals Inc (SBPH)
www.americanbankingnews.com - February 26 at 1:48 AM |
| Spring Bank Pharmaceuticals Inc (SBPH) to Post FY2018 Earnings of ($2.31) Per Share, B. Riley Forecasts
www.americanbankingnews.com - February 23 at 12:28 PM |
| Spring Bank Pharmaceuticals Inc Forecasted to Post FY2022 Earnings of $0.55 Per Share (SBPH)
www.americanbankingnews.com - February 22 at 4:34 PM |
| Spring Bank Pharmaceuticals (SBPH) Price Target Increased to $32.00 by Analysts at Cantor Fitzgerald
www.americanbankingnews.com - February 21 at 2:44 PM |
| Spring Bank Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - February 21 at 10:34 AM |
| Spring Bank Pharmaceuticals Inc (SBPH) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 14 at 11:00 AM |
| Spring Bank Pharmaceuticals Inc (SBPH) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 20 at 8:08 AM |
| Spring Bank Strengthens Management Team to Enhance Operations
finance.yahoo.com - January 9 at 10:41 AM |
| Spring Bank Pharmaceuticals Inc (SBPH) Expected to Announce Earnings of -$0.55 Per Share
www.americanbankingnews.com - January 8 at 5:04 PM |
| Brokerages Anticipate Spring Bank Pharmaceuticals Inc (SBPH) Will Announce Earnings of -$0.55 Per Share
www.americanbankingnews.com - December 23 at 9:18 AM |
| Brokerages Expect Spring Bank Pharmaceuticals Inc (SBPH) Will Post Earnings of -$0.53 Per Share
www.americanbankingnews.com - December 5 at 3:30 PM |
| Spring Bank Pharmaceuticals (SBPH) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - December 2 at 6:16 PM |
| Spring Bank Pharmaceuticals, Inc. (SBPH) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - December 1 at 4:30 PM |
| Spring Bank Pharmaceuticals (SBPH) and PTC Therapeutics (PTCT) Critical Contrast
www.americanbankingnews.com - November 30 at 1:28 AM |
| Spring Bank Pharmaceuticals Announces Positive Top-Line Results from the Second Cohort of Part A of the Phase 2 ACHIEVE Trial
finance.yahoo.com - November 18 at 11:38 AM |
| Zacks: Brokerages Anticipate Spring Bank Pharmaceuticals, Inc. (SBPH) to Post -$0.53 Earnings Per Share
www.americanbankingnews.com - November 17 at 9:30 PM |
| Spring Bank Pharmaceuticals, Inc. (SBPH) Given a $29.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - November 16 at 10:38 AM |
| Analysts Set Expectations for Spring Bank Pharmaceuticals, Inc.'s FY2017 Earnings (SBPH)
www.americanbankingnews.com - November 8 at 11:04 AM |
| Spring Bank to Present at Piper Jaffray’s 29th Annual Healthcare Conference
finance.yahoo.com - November 7 at 9:58 AM |
| Spring Bank Pharmaceuticals, Inc. (SBPH) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 6 at 10:46 AM |
| William Blair Weighs in on Spring Bank Pharmaceuticals, Inc.'s FY2017 Earnings (SBPH)
www.americanbankingnews.com - November 6 at 2:54 AM |
| Head to Head Review: Spring Bank Pharmaceuticals (SBPH) versus Its Peers
www.americanbankingnews.com - November 3 at 9:14 PM |
| Spring Bank Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial and Operational Results
finance.yahoo.com - October 31 at 9:08 AM |
| Spring Bank Pharmaceuticals Announces Additional Inarigivir (formerly SB 9200) Results from the ACHIEVE Trial in HBV Patients at AASLD Conference
finance.yahoo.com - October 20 at 4:57 PM |
| Critical Comparison: Summit Therapeutics PLC (SMMT) & Spring Bank Pharmaceuticals (SBPH)
www.americanbankingnews.com - October 15 at 10:26 PM |
| Financial Analysis: Spring Bank Pharmaceuticals (SBPH) & Its Competitors
www.americanbankingnews.com - October 14 at 6:08 AM |
| Spring Bank Pharmaceuticals Announces Presentation of Positive Preclinical Data on SB 11285 at the 2017 AACR Conference on Tumor Immunology and Immunotherapy
finance.yahoo.com - October 6 at 8:51 AM |
| Spring Bank Pharmaceuticals Announces Two Presentations at the 2017 AASLD Conference in Washington, D.C.
finance.yahoo.com - October 6 at 8:51 AM |
 | ROTY Volume 1 Edition 33: New Leadership In The Model Account, Changes To Format And Trades
seekingalpha.com - September 29 at 11:15 AM |
| William Blair Weighs in on Spring Bank Pharmaceuticals, Inc.'s Q1 2018 Earnings (SBPH)
www.americanbankingnews.com - September 29 at 8:48 AM |
| Financial Survey: Spring Bank Pharmaceuticals (SBPH) versus AveXis (AVXS)
www.americanbankingnews.com - September 29 at 6:42 AM |
| Spring Bank Pharmaceuticals Announces a Poster Presentation of its lead STING Agonist, SB 11285, at the 2017 AACR Conference on Tumor Immunology and Immunotherapy in Boston, MA
finance.yahoo.com - September 20 at 8:44 AM |
Spring Bank Pharmaceuticals (NASDAQ:SBPH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Spring Bank Pharmaceuticals (NASDAQ SBPH) Stock Chart for Saturday, April, 21, 2018
Loading chart…
